A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.

@article{Schwer2008API,
  title={A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.},
  author={Amanda L Schwer and Denise M. Damek and Brian D. Kavanagh and Laurie E. Gaspar and Kevin O. Lillehei and Kelly Stuhr and ChangHu Chen},
  journal={International journal of radiation oncology, biology, physics},
  year={2008},
  volume={70 4},
  pages={993-1001}
}
PURPOSE To determine the maximum tolerated dose (MTD) of fractionated stereotactic radiosurgery (SRS) with gefitinib in patients with recurrent malignant gliomas. METHODS AND MATERIALS A Phase I clinical trial was performed. Eligible patients had pathologically proved recurrent anaplastic astrocytoma or glioblastoma. Patients started gefitinib (250 mg/day) 7 days before SRS and continued for 1 year or until disease progression. SRS was delivered in three fractions over 3 days. The planning… CONTINUE READING
26 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 26 extracted citations

Similar Papers

Loading similar papers…